On September 12, 2024, Keymed Biosciences announced that its independently developed Category 1 innovative drug, Stapokibart Injection, had been officially approved for marketing by China’s National Medical Products Administration (NMPA). The product is indicated for the treatment of adults with moderate-to-severe atopic dermatitis who have an inadequate response to topical therapies or...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek